Literature DB >> 2890628

Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X.

J E Knobloch1, J W Suttie.   

Abstract

A liver microsomal enzyme catalyzes the vitamin K-dependent posttranslational carboxylation of specific glutamyl residues of a limited number of plasma proteins to gamma-carboxyglutamyl residues. The intracellular precursor forms of these proteins are known to contain a homologous basic amino acid-rich propeptide region between the signal peptide region and the amino terminus of the mature protein. This region of the precursor protein has been implicated as a possible recognition site for the carboxylase enzyme. A 20-residue peptide containing the octadecapropeptide of human clotting factor X has now been shown to strongly stimulate the activity of the enzyme toward a noncovalently linked substrate. This stimulatory effect is seen at less than micromolar concentrations and is accompanied by a decrease in the Km of the glutamic acid substrate. These observations raise the possibility that the catalytic activity of other enzymes involved in protein processing may be regulated by a portion of their normal substrates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890628

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Propeptide and glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert its vitamin K epoxidase function from an inactive to an active state.

Authors:  I Sugiura; B Furie; C T Walsh; B C Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Propeptide recognition by the vitamin K-dependent carboxylase in early processing of prothrombin and factor X.

Authors:  R Wallin; R Turner
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

3.  Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency.

Authors:  Dhouha Darghouth; Kevin W Hallgren; Rebecca L Shtofman; Amel Mrad; Youssef Gharbi; Ahmed Maherzi; Radhia Kastally; Sophie LeRicousse; Kathleen L Berkner; Jean-Philippe Rosa
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

4.  Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes.

Authors:  Qiaoli Li; Dorothy K Grange; Nicole L Armstrong; Alison J Whelan; Maria Y Hurley; Mark A Rishavy; Kevin W Hallgren; Kathleen L Berkner; Leon J Schurgers; Qiujie Jiang; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2008-09-18       Impact factor: 8.551

Review 5.  Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase.

Authors:  C Vermeer
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

6.  Group D prothrombin activators from snake venom are structural homologues of mammalian blood coagulation factor Xa.

Authors:  Veena S Rao; Jeremiah S Joseph; R Manjunatha Kini
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

7.  Functional Study of the Vitamin K Cycle Enzymes in Live Cells.

Authors:  J-K Tie; D W Stafford
Journal:  Methods Enzymol       Date:  2016-11-22       Impact factor: 1.600

8.  Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site.

Authors:  B R Hubbard; M M Ulrich; M Jacobs; C Vermeer; C Walsh; B Furie; B C Furie
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Osteocalcin binds tightly to the gamma-glutamylcarboxylase at a site distinct from that of the other known vitamin K-dependent proteins.

Authors:  R J Houben; D Jin; D W Stafford; P Proost; R H Ebberink; C Vermeer; B A Soute
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

10.  Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

Authors:  H H Watzke; A Wallmark; N Hamaguchi; P Giardina; D W Stafford; K A High
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.